- There were around 2,000 new cases of Hodgkin lymphoma in the UK in 2013, that’s more than 5 cases diagnosed every day.
- Hodgkin lymphoma accounts for less than 1% of all new cases in the UK (2013).
- In males in the UK, Hodgkin lymphoma is the 19th most common cancer, with around 1,100 cases diagnosed in 2013.
- In females, there were around 850 cases of Hodgkin lymphoma diagnosed in the UK in 2013.
- Around half (49%) of Hodgkin lymphoma cases in the UK each year are diagnosed in people aged 45 and over (2011-2013).
- Hodgkin lymphoma in England is more common in males living in the most deprived areas. There is no association for females.
- Most Hodgkin lymphoma cases are diagnosed at an early stage.
- Since the late 1970s, Hodgkin lymphoma incidence rates have increased by less than a tenth (7%) in Great Britain, though this includes an increase in females (15%, less than a fifth) and stable rates in males.
- Over the last decade, Hodgkin lymphoma incidence rates have increased by a fifth (20%) in the UK, with similar increases in females (22%) and males (18%).
- Worldwide there were estimated to be around 68,000 new cases of Hodgkin lymphoma in 2008, and more than half of these were in developing countries.
- 1 in 370 men and 1 in 490 women will be diagnosed with Hodgkin lymphoma during their lifetime.
Hodgkin lymphoma statistics
New cases of Hodgkin lymphoma, 2013, UK
Deaths from Hodgkin lymphoma, 2014, UK
Survive Hodgkin lymphoma for 10 or more years, 2010-11, England and Wales
Preventable cases of Hodgkin lymphoma, UK
- There were around 360 Hodgkin lymphoma deaths in the UK in 2014, that’s around 1 death every day.
- Hodgkin lymphoma accounts for less than 1% of all cancer deaths in the UK (2014).
- In males in the UK, Hodgkin lymphoma is the 18th most common cause of cancer death, with around 210 deaths in 2014.
- In females in the UK, there were around 140 Hodgkin lymphoma deaths in 2014.
- More than a third of Hodgkin lymphoma deaths occur in people aged 75 and over.
- Hodgkin lymphoma death rates in the UK have fallen by 75% over the last forty years.
- Hodgkin lymphoma deaths in England are more common in males living in the most deprived areas. There is no association for females.
- Worldwide, around 25,500 people were estimated to have died from Hodgkin lymphoma in 2012, with mortality rates varying across the world.
- In Europe, around 4,600 people were estimated to have died from Hodgkin lymphoma in 2012. The UK mortality rate is 19th lowest in Europe for males and 13th highest for females.
- 8 in 10 (80%) people diagnosed with Hodgkin lymphoma in England and Wales survive their disease for ten years or more (2010-11).
- Almost 9 in 10 (85%) people diagnosed with Hodgkin lymphoma in England and Wales survive their disease for five years or more (2010-11).
- Around 9 in 10 (91%) people diagnosed with Hodgkin lymphoma in England and Wales survive their disease for one year or more (2010-11).
- Hodgkin lymphoma survival is higher in women than men (2010-2011).
- Hodgkin lymphoma survival in England is higher for people diagnosed aged under 40 years old (2009-2013).
- 95% of people in England diagnosed with Hodgkin lymphoma aged 15-39 survive their disease for five years or more, compared with more than a quarter of people diagnosed aged 80 and over (2009-2013).
- Hodgkin lymphoma survival is improving and has increased in the last 40 years in the UK.
- In the 1970s, almost half of people diagnosed with Hodgkin lymphoma survived their disease beyond ten years, now it's 8 in 10.
- 45% of Hodgkin lymphoma cases each year in the UK are linked to major lifestyle and other risk factors.
- A person’s risk of developing Hodgkin lymphoma depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
- Evidence on Hodgkin lymphoma risk factors is limited, mainly because this cancer is relatively rare and comprises many subtypes.
- Epstein-Barr virus is the main potentially avoidable risk factor for Hodgkin lymphoma, linked to an estimated 45% of Hodgkin lymphoma cases in the UK.
- Human immunodeficiency virus (HIV) causes Hodgkin lymphoma.
- Problems with the immune system, overweight and obesity, and smoking may relate to higher Hodgkin lymphoma risk.
- ‘Two-week wait’ is the most common route to diagnosis of Hodgkin lymphoma.
- ‘Two-week wait’ and ’31-day wait’ standards are met by all countries, and ‘62-day wait’ is not met by any country for haematological cancers.
- Around 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- 9 in 10 of patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for Hodgkin lymphoma in the UK are; incidence 2013, mortality 2014 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2010-2012 due to the small number of cases.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Overall, the evidence on Hodgkin lymphoma risk factors is limited, mainly because of this cancer's relative rarity and diversity. Studies which group together different morphological subtypes of Hodgkin lymphoma may be confounded if those subtypes have differing aetiologies.
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013.
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Hodgkin lymphoma is part of the group 'Haematological cancers' for cancer waiting times data. Codes vary per country but broadly include: Hodgkin lymphoma, follicular and non-follicular lymphoma, mature T/NK-cell lymphoma, other and unspecified types of NHL, other and unspecified types of T/NK-cell lymphoma, malignant immunoproliferative diseases, myeloma, lymphoid, myeloid and monocytic leukaemia, some other leukaemia of specific or unspecified cell type, and other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK statistics content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.